Verrica Pharmaceuticals Inc.
NASDAQ:VRCA
5.06 (USD) • At close September 8, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Revenue
| 7.566 | 5.124 | 9.032 | 12 | 0 |
| Cost of Revenue
| 1.853 | 0.746 | 0.725 | 0.472 | 0.229 |
| Gross Profit
| 5.713 | 4.378 | 8.307 | 11.528 | -0.229 |
| Gross Profit Ratio
| 0.755 | 0.854 | 0.92 | 0.961 | 0 |
| Reseach & Development Expenses
| 11.84 | 20.295 | 12.198 | 15.929 | 15.673 |
| General & Administrative Expenses
| 58.018 | 47.302 | 17.405 | 26.979 | 24.508 |
| Selling & Marketing Expenses
| 0.004 | 0.004 | 0 | 0 | 0 |
| SG&A
| 58.822 | 47.305 | 17.405 | 26.979 | 24.508 |
| Other Expenses
| 0.97 | 2.537 | 0 | -0.472 | -0.229 |
| Operating Expenses
| 71.632 | 70.137 | 29.603 | 42.436 | 39.952 |
| Operating Income
| -65.919 | -65.759 | -21.296 | -30.908 | -40.181 |
| Operating Income Ratio
| -8.713 | -12.834 | -2.358 | -2.576 | 0 |
| Total Other Income Expenses Net
| -10.66 | -1.236 | -3.191 | -4.172 | -2.513 |
| Income Before Tax
| -76.579 | -66.995 | -24.487 | -35.08 | -42.694 |
| Income Before Tax Ratio
| -10.121 | -13.075 | -2.711 | -2.923 | 0 |
| Income Tax Expense
| 0 | 0 | 0 | 0 | 0 |
| Net Income
| -76.579 | -66.995 | -24.487 | -35.08 | -45.497 |
| Net Income Ratio
| -10.121 | -13.075 | -2.711 | -2.923 | 0 |
| EPS
| -14.78 | -14.78 | -7.17 | -12.97 | -17.08 |
| EPS Diluted
| -14.78 | -14.78 | -7.17 | -12.97 | -17.08 |
| EBITDA
| -65.898 | -62.197 | -21.597 | -30.313 | -39.432 |
| EBITDA Ratio
| -8.71 | -12.138 | -2.391 | -2.526 | 0 |